// App-Quantinova.ai

3688 : Results of a Phase II Trial of Brentuximab Vedotin (SGN-35) for CD30+ Cutaneous T-Cell Lymphomas and Lymphoproliferative Disorders

Researchers

Presenter

  • Michael Tetzlaff

Principal Investigators

  • Audra L Clos

  • Pamela Gangar

  • Rakhshandra Talpur

Medical Centers

  • Dermatology, Univ of Texas MD Anderson Cancer Ctr, Houston, TX

  • Hematopathology, University of Texas - MD Anderson Cancer Center, Houston, TX

  • Dermatology, Univ of Texas MD Anderson Cancer Ctr, Houston, TX

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Lympho proliferative disease

  • Lymphomatoid papulosis

  • Deep vein thrombosis

  • Mycosis fungoides

  • Cardiorenal syndrome

  • T-cell lymphoma

  • Hodgkin's Lymphoma

  • Neutropenia

  • Angina

  • Peripheral neuropathy

  • Venous thrombosis

  • Lymphomas

  • Cutaneous T-cell lymphoma

Biomarkers

  • Cluster of Differentiation 30

Drug/Treatment

  • monomethyl auristatin E

  • Adcetris

Outcome

  • N/A

Study Design

  • open label

  • double blind/blinded

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved